• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Afatinib

Pharmacogenomic Information
  

Drug Link
in Drugs@FDA
Therapeutic AreaHUGO SymbolReferenced
Subgroup
Labeling Sections with
Pharmacogenomic
Information
AfatinibOncologyEGFREGFR exon 19 deletion
or exon 21 substitution
(L858R) mutation positive
Indications and Usage
Dosage and Administration
Adverse Reactions
Clinical Pharmacology
Clinical Studies
Patient Counseling Information

 

back to Table of Pharmacogenomic Biomarkers in Drug Labeling